Corient Private Wealth LP Has $4.92 Million Stock Holdings in AbbVie Inc. $ABBV

Key Points

• Corient Private Wealth LP dramatically increased its AbbVie stake by 787.7% in the second quarter, adding 17.36 million shares and reporting ownership of 19.56 million shares. Institutional investors collectively hold 70.23% of AbbVie’s stock.
• Analysts maintain a generally positive outlook, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $275.95; recent targets range as high as $290.
• AbbVie’s growth products, including Skyrizi and Rinvoq, helped drive quarterly revenue growth of 10.2% and an earnings beat, while the company offers a 2.7% dividend yield. However, declining Humira sales and initial earnings dilution from the Apogee acquisition remain key risks.

Corient Private Wealth LP boosted its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 787.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,562,230 shares of the company's stock after purchasing an additional 17,358,580 shares during the period. Corient Private Wealth LP owned about 1.11% of AbbVie worth $4,923,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp boosted its position in AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company's stock worth $18,494,193,000 after buying an additional 1,119,274 shares during the period. Geode Capital Management LLC increased its position in AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. Bank of America Corp DE raised its stake in shares of AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock valued at $5,900,617,000 after acquiring an additional 356,394 shares during the last quarter. Norges Bank bought a new position in shares of AbbVie during the fourth quarter valued at $5,865,055,000. Finally, Capital Research Global Investors lifted its holdings in shares of AbbVie by 0.7% during the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company's stock worth $5,805,530,000 after purchasing an additional 177,370 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. UBS Group upped their price target on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. BNP Paribas Exane upped their price target on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Finally, Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and a consensus target price of $275.95.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

AbbVie Stock Performance

NYSE:ABBV opened at $256.27 on Friday. The firm's fifty day moving average is $254.66 and its 200-day moving average is $230.06. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The firm has a market cap of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie's dividend payout ratio (DPR) is 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source